Kenneth C. Anderson, M.D.
Scientific Founder
Kraft Family Professor of Medicine
Harvard Medical School / Dana-Farber Cancer Institute

Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor.

After graduating from Johns Hopkins Medical School, he trained in internal medicine at Johns Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last four decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted and immune therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.

Nikhil C. Munshi, M.D.
Scientific Founder
Professor
Harvard Medical School / Dana-Farber Cancer Institute

Dr. Munshi received his MD from Maharaja Sayjirao University, India, in 1984. He completed his postgraduate training in Internal Medicine at SSG Hospital and Maharaja Sayjirao University, followed by fellowships at Johns Hopkins Oncology Center and Indiana University Medical Center. In 2001, he joined Dana-Farber Cancer Institute and is currently the Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center.

Jooeun Bae, Ph.D.
Scientific Founder
Lead Investigator
Harvard Medical School / Dana-Farber Cancer Institute

Dr. Bae is a Lead Investigator at Dana-Farber Cancer Institute and Harvard Medical School with greater than 25 years of translational cancer research focused on the identification and development of immunotherapeutic applications under collaborations with academics and bio-pharmaceutical companies. Dr. Bae received her Master of Science in Immunology from University of Maryland at Baltimore and her Ph.D. in Biomedical Science from Virginia Polytechnic Institute and State University.  After completing her post-doctoral fellowship in Bio-engineering Science at the University of Rochester in New York, she served as an Assistant Professor at Rush University Medical Center (Chicago, IL) and in leadership roles for several biotech companies.

Dennis Klinman, M.D., Ph.D.
Chief Scientific Officer,
Cobro Ventures

Dr. Klinman served as Principal Investigator at the National Cancer Institute, NIH, and the Center for Biologics of the FDA. His scientific expertise spans the fields of vaccinology, cancer immunotherapy and autoimmunity, having published over 350 articles in those areas. He currently serves as the CSO of Cobro Ventures.

James Mulé, Ph.D.
Executive VP/Associate Director for Transitional Research
Moffit Cancer Center

Dr. Mulé serves as Executive Vice President and Associate Center Director for Translational Research at Moffitt Cancer Center.

David Scheinberg, M.D., Ph.D.
Vincent Astor Chair/Chair of Molecular Pharmacology and Chemistry
Sloan-Kettering Institute

Dr. Scheinberg is currently the Vincent Astor Chair and Chairman of the Molecular Pharmacology and Chemistry Program at the Sloan-Kettering Institute, Professor of Medicine and Pharmacology and Co-chair of the Pharmacology graduate program at the Weill-Cornell University Medical College and Professor in the Gerstner-Sloan Kettering Graduate School at MSKCC.

Carl Novina, M.D., Ph.D.
Associate Professor of Medicine
Harvard Medical School / Dana-Farber Cancer Institute

Dr. Novina received his MD from Columbia University, College of Physicians and Surgeons in 2000 and his PhD from Tufts University, Sackler School of Graduate Biomedical Sciences in 1998. He completed his postdoctoral fellowship at the Massachusetts Institute of Technology in the laboratory of Nobel Laureate Dr. Phillip Sharp. In 2004, he joined Dana-Farber Cancer Institute & Harvard Medical School. His laboratory integrates basic science with development of advanced technologies to accelerate the translation of biological discoveries into novel therapies.

Arthur Becker
Chief Executive Officer

Arthur is the current CEO of Oncopep, a cancer vaccine company with proprietary peptides about to begin Phase II trials in metastatic Triple Negative Breast Cancer (TNBC). He is also the Chairman of the Board of VisgenX, a start up focussed on a novel approach to “Dry” Age Related Macular Degeneration (Dry AMD). He is a Venture Partner with CoBro Ventures and is on the Boards of NextRNA, AI Proteins and OncoPep. He is also a Managing Member of Madison Technology, LLC, an investment firm focused on early-stage Fin Tech and Web 3 ventures. Becker was formerly the Chairman & CEO of Zinio, LLC (2012-2015) the world’s largest digital newsstand. Prior to joining Zinio, Mr. Becker was the CEO of NaviSite, a NASDAQ quoted company that provided internet technology and hosting services to businesses in the US and UK from 2002-2010.

Michael D. Krepps
Chief Operating Officer

Mike leads all strategic and operational efforts for OncoPep. He also serves as an EIR with Cobro Ventures. Prior to joining OncoPep as COO, Mike worked as a scientist, consultant, entrepreneur, and VC.

Mike’s most recent role was with the American Cancer Society’s VC fund (BrightEdge). In this role, he led the investment team, managed diligence efforts of all potential investment opportunities, and sat on the Investment Committee. During this time, Mike held Board Observer roles at Navigating Cancer, Tmunity, Freenome, and Interius. Prior to joining BrightEdge, Mike worked as an Associate Principal in the Life Sciences Practice of the CRA consulting group where he led global engagements in therapeutic area strategy, asset strategy, pipeline optimization, pricing & market access, M&A, and corporate strategy, primarily in oncology and immunology.

Mike was originally trained as a scientist, and his scientific experience includes co-founding SynActive Biosciences, a startup focused on stem cell-derived neuron technologies,­ and working as a Program Manager/Senior Scientist in the Biosciences Division at the Department of Defense. At the Department of Defense, Mike researched immunology and infectious disease with a focus on emerging pathogens and bio-terrorism threat agents. Additionally, he has authored many publications and has presented his research at leading academic conferences.

Mike received a Master of Science in genetics and a Bachelor of Science in bacteriology from the University of Wisconsin-Madison and an MBA in finance, strategy, and entrepreneurship from the University of Chicago Booth School of Business. He is conversant in German and Spanish.

Victor Moyo
Chief Medical Officer

Victor is the Chief Medical Officer of Oncopep.  He provides strategic clinical leadership to ensure delivery of OncoPep’s efforts to develop transformative immunotherapeutics.   Victor is a graduate of the University of Zimbabwe School of Medicine. He completed his internal medicine residency training at the George Washington University Hospital and his fellowship training in Hematology / Oncology at The Johns Hopkins Hospital. He was previously an Assistant Professor of Medicine at the University of Connecticut Health Center.  Victor’s core clinical development expertise includes design, implementation, and analysis of Phase I-IV oncology studies. His regulatory experience includes, Pre-IND/IND, End of Phase 1 and 2, NDA submissions.

Prior to Oncopep, Victor served in roles of increasing responsibility at Ortho-Biotech (JNJ/Janssen), Merrimack Pharmaceuticals, L.E.A.F. Pharmaceuticals and LEAF4Life Inc. Most recently he served as Executive Vice President, Chief Medical Officer, and Head of R&D for the LEAF family of companies, where he helped establish a team and strategically oversaw all the Research and development efforts.

At Merrimack he worked on, multiple programs including the design and implementation of clinical development strategy that ultimately led to the approval of OnivydeÒ in metastatic pancreatic cancer.  Another product that he recently helped to develop, LEAF-4L6715 has been granted compassionate access in France for patients with critical COVID-19 on a ventilator. Victor is also a named inventor on numerous patents.

Sanghyuck Nam
Chief Financial Officer

As one of OncoPep’s first new employees, Sanghyuck joined the Company in November 2020 as the representative of the operations of the company in Republic of Korea.

Since then Sanghyuck has been involved business development with prominent bio companies in Korea and responsible for overseeing our relationships with OncoPep’s Korean colleagues and investors. Sanghyuck also acts as a liaison with OncoPep’s Korean legal firm, accounting firm, audit firm, Korea Securities Depository, KRX, and Shinhan Financial Group (OncoPep’s Underwriter for the public offering).

Starting his career as a credit analyst at a multinational IT company, Sanghyuck moved to offices of Abu Dhabi and Singapore of major construction companies and worked as a CFO. He has also worked as an investor relations officer, consultant, and fundraising specialist.

Jaehan Park
Chief Strategy Officer

Jaehan is the Chief Strategy Officer of OncoPep, Inc. He leads business & corporate strategy and business development. For the past two decades, Jaehan has served the world’s leading innovative biotech/high-tech companies as an expert in strategy and business development, contributing to their phenomenal growth and globalization.

One of his key strengths is his ability to design winning growth strategies and execution plans based on his business acumen and deep understanding of science. He also has an extensive international network and expertise in comprehensive business development processes, especially in the field of novel therapeutics and diagnostics.

Prior to joining OncoPep, he founded NAUGEN, Inc., an innovation accelerator that incubates globally sourced “Novel”, “Advanced” and “Unprecedented” (NAU) technology and products. There, he has incubated and consulted high-potential biotech start-ups collaborating with pioneering innovators of revolutionary science. One of his major footprints in biotech is his experience in NeoImmuneTech, Inc. As its Chief Strategy Officer, he contributed to the development of novel cancer immunotherapeutics by creating a transformative strategy and enabling collaboration with global pharmaceutical companies and prestigious universities/hospitals. As a Senior Manager, Business Development of Genexine, Inc., he also contributed to the exponential growth of the leading South Korean biotech developing novel biologics and DNA vaccines in various therapeutic indications. He began his career as a business consultant in Accenture, Ltd., a global leading management consulting company, where he provided strategy and process innovation services to many global leading high-tech companies e.g., Samsung, LG, SK, etc.

He has a B.S. in Physics from Seoul National University, and a Masters of Engineering in Biotechnology from Yonsei Graduate School of Engineering. He has three young sons and serves international youth organizations as a youth mindset and spiritual educator.

Jennifer Bukoff
Quality Systems Controller

After graduating with a Bachelor of Science from the University of Florida, Jen began her biotech career in 2002. For more than 10 years, she trained and worked within multiple disciplines both QC and QA based, several of those years in management level positions. In 2015, Jen transitioned into a QA consulting role, became a certified auditor and has a diverse portfolio of QMS building experience.

Doris Peterkin
Head of Vaccine Development

Doris has served in a variety of leadership roles for biopharmaceutical and healthcare companies including Genzyme (now Sanofi Genzyme). Most recently, Doris was Chief Executive Officer at Healagenics, a health-care technology firm focused on the wound-care market, and Vice President of Market Development at Antigenics (now Agenus), a cancer vaccine development company. Doris received her Bachelor of Science from Virginia Polytechnic Institute and State University and her Master of Business Administration from Boston University.

Tina Soulis
Director/Australia

Dr Tina Soulis has over 27 years of working in the healthcare (pharmaceuticals and devices), biotechnology, academic research, clinical research and management sectors in senior roles including: CEO of a Contract Research Organization, Director of a successful ASX200 company, VP of Clinical Strategy and Development with an innovative biotechnology company and now, Founder and Director of her own clinical consultancy company. A dynamic and strategic leader, Tina has an extensive network of stakeholders all over the world and experience in many therapeutic areas across all phases on development.

Tina holds academic appointments with University of Melbourne (teaching and supporting undergraduate pharmacology, honorary fellowship with The Florey Institute of Neuroscience and Mental Health), and is a regular invited speaker locally and globally on a broad range of topics on Clinical trials, Research, Innovation and Industry Collaboration. Tina is one of the few Australian clinical development leaders who has successfully taken products from lab to regulatory approval.